FDA expands approved use of Cyramza to treat aggressive non-small cell lung cancer

The U.S. Food and Drug Administration today expanded the approved use of Cyramza (ramucirumab) to treat patients with metastatic non-small cell lung cancer (NSCLC). The most common type of lung cancer, NSCLC occurs when cancer cells form in the tissues of the lung. The National Cancer Institute…

Source:FDA expands approved use of Cyramza to treat aggressive non-small cell lung cancer